Home Top Stories Nigeria must develop local API capacity, says Pharma Expo CEO

Nigeria must develop local API capacity, says Pharma Expo CEO

0
21

 

Paresh Jurmarwala

Nigeria must build local capacity to produce active pharmaceutical ingredients (APIs) to reduce dependence on imported medicines, conserve foreign exchange, and strengthen the country’s pharmaceutical manufacturing base, Paresh Jurmarwala, founder and chief executive officer of GPE Expo Limited, said.

Jurmarwala, who has been involved in pharmaceutical exhibitions and industry development across several countries, said Nigeria could learn from countries such as India and Bangladesh, where pharmaceutical manufacturing has progressively moved beyond finished products to producing raw materials and other high-value inputs. Speaking in an exclusive interview with Pharmanews at the opening of the 2026 Nigeria Pharma Manufacturers’ Expo in Lagos, he said Nigeria should pursue what he described as “backward integration”, under which local manufacturers gradually move from producing finished medicines into APIs and other stages of the pharmaceutical value chain. “I will give you another example to make it easy to understand. It was the same situation in India a few years ago, when India was not manufacturing much API,” he said.

According to Jurmarwala, India initially concentrated on finished pharmaceutical products while China developed a strong position in API production, but the country subsequently began building its own local API manufacturing capacity. “So, Nigeria should pursue backward integration,” he said, citing Bangladesh as another example of how government intervention can support the development of pharmaceutical raw materials. “After developing more than 350 pharmaceutical companies, the country took another step. The government created an API park, and 45 API manufacturers have established their operations there,” he said.

Jurmarwala said the expansion of local pharmaceutical manufacturing would ultimately depend on the size and purchasing power of the domestic market, arguing that growing demand would make local production of pharmaceutical ingredients increasingly commercially viable. “When people have greater purchasing capacity, the market grows,” he said, illustrating the point with paracetamol. According to him, a market requiring five tonnes of an ingredient could eventually expand to 50 tonnes, creating sufficient demand to justify domestic production. “When the requirement reaches 50 tonnes, people will begin manufacturing locally. This is how the whole process works,” he said.

He said Nigeria’s pharmaceutical industry could therefore evolve progressively from finished medicine production into APIs, clinical research and newer areas such as biosimilars, provided the foundations for manufacturing were strengthened. “Initially, we have to start manufacturing. Then we move into APIs, clinical research organisations and, subsequently, newer areas such as biosimilars. Then we can begin undertaking all kinds of innovation,” he said.

Jurmarwala also identified domestic consumption as one of Africa’s major advantages in developing pharmaceutical manufacturing, arguing that a large local market could support production while reducing pressure on foreign exchange and creating employment. “The biggest advantage is local consumption,” he said. “If you start manufacturing locally, you will definitely save foreign exchange. When you manufacture locally, the government also benefits.” He added that Africa’s large population and healthcare needs presented opportunities not only for pharmaceutical manufacturing but also for wider healthcare investment, including hospital partnerships, technology transfer and other forms of industrial collaboration. “Africa is a huge market, and people have now started thinking very seriously about this, not only in the pharmaceutical industry but also in the wider healthcare sector,” he said.

Jurmarwala, who said GPE Expo has organised pharmaceutical exhibitions in more than 11 countries, also defended the role of industry exhibitions in supporting local manufacturing, saying the company’s activities extend beyond bringing exhibitors into Nigeria. “We are not a company that simply comes here, organises an exhibition and goes back,” he said, noting that this was his 16th year in Nigeria. According to him, the company provides pharmaceutical manufacturers with information about technologies, production processes, new drugs and molecules, as well as international manufacturing standards, helping them understand how to improve their operations and compete in the global market. “We always provide pharmaceutical industries with information and knowledge about what is available in the world market, how they can start production, and how they can work with new drugs and molecules so that they can compete in the global market,” he said.

He added that manufacturers were also exposed to WHO GMP and EU GMP requirements to help them improve production standards and prepare for export markets. Jurmarwala said Nigeria’s pharmaceutical manufacturing sector continued to face challenges, particularly unstable electricity supply, but maintained that such obstacles could be addressed if manufacturers developed appropriate alternatives without undermining the cost competitiveness of locally produced medicines.

He also linked affordable medicines to government procurement and quality standards, arguing that stronger government purchasing of locally manufactured products could encourage companies to invest in internationally recognised production standards. “When the government starts implementing WHO GMP standards, it means quality products. The government will buy quality products, and once it starts buying locally manufactured quality products, local manufacturers will invest in WHO GMP and other compliance requirements,” he said. He added that greater competition among manufacturers, alongside appropriate pricing policies, could help improve affordability and public confidence in locally produced medicines, while increased public awareness through social media and other platforms was helping consumers understand quality standards such as WHO GMP requirements.

Jurmarwala further said Nigerian manufacturers were showing growing interest in expanding their operations, investing in compliance and exploring export opportunities in neighbouring countries. “They have plans to export to neighbouring countries. This means that the people have a lot of interest, while the government is also supporting them, directly or indirectly, and encouraging them to manufacture and expand their operations,” he said.

He urged African countries to invest in pharmaceutical technology and human capacity, particularly by enabling doctors, pharmacists and other professionals to acquire specialised knowledge abroad and transfer those skills back to the continent. “Nowadays, a lot of technology is available. African countries can acquire the technology, while doctors, pharmacists and other professionals can travel abroad to learn how the technology works,” he said. Jurmarwala said such investments, combined with Africa’s growing domestic market, could support the gradual development of a more integrated pharmaceutical manufacturing ecosystem on the continent.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here